Puja Sharma

Dr. Puja Sharma


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPuja Sharma
Puja Sharma
WDWaldemar Debinski
Waldemar Debinski
Among primary brain tumors, malignant gliomas are notably difficult to manage. The higher-grade tumors represent an unmet need in medicine. There have been extensive efforts to implement receptor-targeted therapeutic approaches directed against gliomas. These approaches include immunotherapies, such as vaccines, adoptive immunotherapy, and passive immunotherapy. Targeted cytotoxic radio energy and pro-drug activation have been designed specifically for brain tumors. The field of targeting through receptors progressed significantly with the discovery of an interleukin 13 receptor alpha 2 (IL-13RA2) as a tumor-associated receptor over-expressed in most patients with glioblastoma (GBM) but not in normal brain. IL-13RA2 has been exploited in novel experimental therapies with very encouraging clinical responses. Other receptors are specifically over-expressed in many patients with GBM, such as EphA2 and EphA3 receptors, among others. These findings are important in view of the heterogeneity of GBM tumors and multiple tumor compartments responsible for tumor progression and resistance to therapies. The combined targeting of multiple receptors in different tumor compartments should be a preferred way to design novel receptor-targeted therapeutic approaches in gliomas.

23 April 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PSPuja Sharma
Puja Sharma
CRCallie Roberts
Callie Roberts
DHDenise Herpai
Denise Herpai
IFIzabela D. Fokt
Izabela D. Fokt
WPWaldemar Priebe
Waldemar Priebe
WDWaldemar Debinski
Waldemar Debinski
Glioblastoma (GBM) is a complex and heterogeneous tumor that warrants a comprehensive therapeutic approach for treatment. Tumor-associated antigens offer an opportunity to selectively target various components of the GBM microenvironment while sparing the normal cells within the central nervous system. In this study, we conjugated a multivalent vector protein, QUAD 3.0, that can target four receptors: EphA3, EphA2, EphB2, and also IL-13RA2, spanning virtually 100% of the GBM microenvironment, to doxorubicin derivatives. The conjugates effectively bound to all four receptors, although to varying degrees, and delivered cytotoxic loads to both established and patient-derived GBM cell lines, with IC50 values in the low nM range. The conjugates were also non-toxic to animals. We anticipate that the QUAD 3.0 Dox conjugates will be further used in preclinical models and possibly clinics in the foreseeable future.

5 November 2018 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
PSPuja Sharma
Puja Sharma
DHDenise Herpai
Denise Herpai
JRJohn Rossmeisl
John Rossmeisl
STStephen Tatter
Stephen Tatter
WDWaldemar Debinski
Waldemar Debinski
Glioblastoma is a heterogeneous tumor for which all single-targeted agents failed. Being that a cytotoxic cocktail targeting IL-13RA2 and EphA2 receptors is effective in the treatment of spontaneous gliomas in dogs, we have been further pursuing molecular resection by targeting four tumor-specific/associated receptors at once: IL-13RA2, EphA2, EphA3 and EphB2. These receptors are over-expressed in most GBM tumor compartments responsible for tumor progression and recurrence. To this end, we have engineered a protein based on an immunoglobulin scaffold with a ligand targeting the three Eph receptors, ephrinA5 (eA5), at the N-terminal end and a ligand targeting IL-13RA2, IL-13.E13K, at the C-terminal end (QUAD). However, the protein produced in insect cells had frequently two bands on SDS-PAGE. We have therefore decided to change the order of the ligands and placed the ligand targeting IL-13RA2 at the N-terminal end of the protein and the other ligand and the C-terminus. We also started using High-Five cells for codon and yield optimization. The newer construct is produced as a single protein band on the SDS-PAGE and Western blot and can be purified to homogeneity. It bound all four receptors effectively in ELISA while the affinity toward the EphA3 was even better than in the original multivalent compound. We also obtained higher yields of the protein. To make our vector even more versatile, we have added a C-terminal cysteine providing a free thiol group for chemical conjugation with drugs. The QUAD-Cys was also obtained as a single band protein homodimer and the multi-targeted protein bound effectively to all targets of interest. Thus, we have optimized the production of a functional multivalent targeted vector protein for making drug conjugates. QUAD and QUAD-Cys based conjugates will be tested for their utility in glioma treatment using relevant clinical models like spontaneous brain tumors in dogs.